[Form 4] Parabilis Medicines, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Parabilis Medicines’ major Soleus-affiliated holders increased their indirect stake through both conversion and open-market buying. On June 11, 2026, Soleus investment funds converted 527,070 shares of Series F Preferred Stock into common stock at $9.48 per share in an automatic conversion tied to the company’s initial public offering.
The same day, Soleus-related entities purchased an additional 500,000 common shares in open-market transactions at $20.00 per share, bringing their reported indirect common stock holdings to 1,027,000 shares for Section 16 reporting purposes.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 500,000 shares ($10,000,000)
Net Buy
4 txns
Insider
Levy Guy, Soleus Private Equity Fund III, L.P., Soleus Private Equity GP III, LLC, Soleus PE GP III, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, Soleus Capital Master Fund, L.P., Soleus Capital, LLC, Soleus Capital Group, LLC
Role
null | null | null | null | null | null | null | null | null
Bought
500,000 shs ($10.00M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series F Preferred Stock | 527,070 | $0.00 | -- |
| Purchase | Common Stock, par value $0.0001 per share | 375,000 | $20.00 | $7.50M |
| Purchase | Common Stock, par value $0.0001 per share | 125,000 | $20.00 | $2.50M |
| Conversion | Common Stock, par value $0.0001 per share | 527,070 | $9.48 | $5.00M |
Holdings After Transaction:
Series F Preferred Stock — 0 shares (Indirect, See footnote);
Common Stock, par value $0.0001 per share — 1,027,000 shares (Indirect, See footnote)
Footnotes (1)
- The Series F Preferred Stock automatically converted into shares of the common stock of the issuer immediately prior to the closing of the issuer's initial public offering without payment of consideration and had no expiration date. The reportable securities are owned directly by Soleus Private Equity Fund III, L.P. ("Soleus PE"). Soleus Private Equity GP III, LLC ("Soleus PE GP") is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management, L.P. ("SCM") is the investment manager for Soleus PE, and Soleus GP, LLC ("Soleus GP") is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and Soleus GP. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP disclaims beneficial ownership of the securities held by Soleus PE other than for the purpose of determining their obligations under Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such securities for any other purpose, except to the extent of their respective pecuniary interests therein. The reportable securities are owned directly by Soleus Capital Master Fund, L.P. ("MF"). Soleus Capital LLC is the sole general partner of MF, Soleus Capital Group, LLC ("SCG") is the sole managing member of Soleus Capital, LLC, SCM is the investment manager of MF, and Soleus GP is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and Soleus GP. Each of Mr. Levy, SCG, Soleus Capital LLC, SCM and Soleus GP disclaims beneficial ownership of the securities held by MF other than for the purpose of determining their obligations under Section 16 of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such securities for any other purpose, except to the extent of their respective pecuniary interests therein.
